

Larry C. Buckelew joins Gambro as President, Gambro Healthcare US

Stockholm, Sweden, May 3, 2000 - Gambro AB (OM Stockholm Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that Larry C. Buckelew has been appointed President, Gambro Healthcare US with the responsibility for the US operations. In this position, which is new, he will report directly to Brad Nutter, President of Gambro Healthcare. Larry C. Buckelew will join Gambro in two weeks, on May 15.

Larry C. Buckelew joins Gambro from a position as President, TFX Medical Group which has about USD 400 M in revenues and about 4,400 employees. It is part of Teleflex Inc. (NYSE: TFX). He has more than 25 years of experience from the health-care products and service industry in the US. His comprehensive and successful career includes various management positions in companies with products and services for the hospital, laboratory and home care markets.

“I am extremely happy to have Larry C. Buckelew join Gambro Healthcare”, says Brad Nutter. “He will lead the US operations with about USD 1.2 billion in revenues and about 10,000 employees dedicated to improving people’s lives who suffer from renal failure. He has an excellent track record and I am sure he can bring the US operations forward in a very positive way.”

For further information please contact:

Bengt Mod er, Senior Vice President, Corporate Communications, tel. +46-8-613 65 00,
+46-70-513 65 33

Anna Augustson, European Investor Relations Manager, tel. +46-8-613 65 35, +46-70-513 65 34
Cindy Lyman or Kerry Schneider, Citigate Dewe Rogerson, New York , tel. +1-212-688 6840

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology (BCT). Gambro is one of the leading providers of kidney dialysis services in the world. Gambro treats about 44,200 patients in 588 clinics worldwide. Renal care products comprise dialyzers, dialysis machines, blood lines and dialysis concentrates. BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 20 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries.

Gambro AB
A public company (publ)
Reg no. 556041-8005
Hamngatan 2, P O Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30
info@gambro.com
www.gambro.com